Evaluation of antimetastatic activity and systemic toxicity of camptothecin-loaded microspheres in mice injected with B16-F10 melanoma cells.
OBJECTIVE
The aim of this work was to evaluate the pulmonary antimetastatic activity and the systemic toxicity of camptothecin-loaded microspheres.


METHODS
PCL microspheres containing camptothecin (CPT) were prepared by the emulsion solvent/evaporation method and characterized according to their encapsulation efficiency, particle size, morphology, and drug release. The ability of CPT to inhibit the lung metastasis was verified using an experimental mouse model intravenously injected with metastatic B16- F10 melanoma cells. The microspheres and the free drug were given intraperitoneally at a dose of 7 mg/kg at intervals of three or five days for 24 days. The systemic toxicity of CPT was evaluated by weight measurements, survival and hemograms of the animals.


RESULTS
The encapsulation efficiency was nearly 80%. The drug release was complete after 72 hours, but the burst effect increased from 7% to 35% with the increase in CPT content in the particles. It was observed during the in vivo essays that all groups treated with CPT had a decrease of nearly 70% in the number of lung metastases. However, systemic toxicity was verified in animals that received the free drug.


CONCLUSIONS
Camptothecin-loaded microspheres demonstrated similar therapeutic efficacy when compared to those of the free drug, but the toxicity was significantly reduced.
Dora
Cristiana Lima
CL
Laboratório de Farmacotécnica, Departamento de Ciéncias Farmacéuticas, Centro de Ciéncias da Saúde, Universidade Federal de Santa Catarina, Campus Trindade, Florianópolis, Brazil.
Alvarez-Silva
Marcio
M
Trentin
Andréa Gonçalves
AG
de Faria
Tatiany Jovita
TJ
Fernandes
Daniel
D
da Costa
Robson
R
Stimamiglio
Marco
M
Lemos-Senna
Elenara
E
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000633:toxicity; D002166:Camptothecin / Q000008:administration & dosage* / Q000633:toxicity; D002214:Capsules; D003692:Delayed-Action Preparations; D004195:Disease Models, Animal; D004337:Drug Carriers; D016503:Drug Delivery Systems; D008545:Melanoma / Q000517:prevention & control*; D051379:Mice; D008863:Microspheres; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009368:Neoplasm Transplantation; D010316:Particle Size
D000972:Antineoplastic Agents, Phytogenic; D002214:Capsules; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D002166:Camptothecin